Cyclopharm Ltd has released a press release.
CYC Update - R&D Tax Incentive, USFDA, German Litigation
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Cyclopharm
- CANM Endorses Technegas
- Positive USFDA Meeting - Technegas sales expected in 2019
- Cyclopharm 2018 First Half Preliminary Headline Update
- CYC 2018 AGM Presentation
- Better Defining Airways Disease with Technegas
Later from Cyclopharm
- Announcement of buy-back - Appendix 3C
- CYC Half Yearly Reports and Accounts
- CYC Business Update
- Pause in Trading
- Agreement to utilise cyclotron facility assets
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm